Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Total Valuation
Gilead Sciences has a market cap or net worth of $122.02B. The enterprise value is $131.96B.
Market Cap$122.02B
Enterprise Value$131.96B
Share Statistics
Gilead Sciences has 1,246,634,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,246,634,500
Owned by Insiders0.09%
Owned by Institutions0.52%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.36%.
Return on Equity (ROE)0.02
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)2.36%
Return on Capital Employed (ROCE)0.04
Revenue Per Employee1.63M
Profits Per Employee27.27K
Employee Count17,600
Asset Turnover0.49
Inventory Turnover3.66
Valuation Ratios
The current PE Ratio of Gilead Sciences is 239.97. Gilead Sciences’s PEG ratio is -2.62.
PE Ratio239.97
PS Ratio0.00
PB Ratio5.96
Price to Fair Value5.96
Price to FCF11.18
Price to Operating Cash Flow10.64
PEG Ratio-2.62
Income Statement
In the last 12 months, Gilead Sciences had revenue of 28.75B and earned 480.00M in profits. Earnings per share was 0.38.
Revenue28.75B
Gross Profit22.50B
Operating Income1.66B
Pretax Income690.00M
Net Income480.00M
EBITDA4.43B
Earnings Per Share (EPS)0.38
Cash Flow
In the last 12 months, operating cash flow was 10.37B and capital expenditures -271.00M, giving a free cash flow of 9.95B billion.
Operating Cash Flow10.37B
Free Cash Flow9.95B
Free Cash Flow per Share7.98
Dividends & Yields
Gilead Sciences pays an annual dividend of $0.79, resulting in a dividend yield of 3.16%
Dividend Per Share$0.79
Dividend Yield3.16%
Payout Ratio40.01%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.35
52-Week Price Change48.86%
50-Day Moving Average107.72
200-Day Moving Average92.25
Relative Strength Index (RSI)34.53
Average Volume (3m)9.14M
Important Dates
Gilead Sciences upcoming earnings date is Aug 5, 2025, TBA Not Confirmed.
Last Earnings DateApr 24, 2025
Next Earnings DateAug 5, 2025
Ex-Dividend DateJun 13, 2025
Financial Position
Gilead Sciences as a current ratio of 1.60, with Debt / Equity ratio of 0.00%
Current Ratio1.60
Quick Ratio1.45
Debt to Market Cap0.23
Net Debt to EBITDA3.77
Interest Coverage Ratio1.70
Taxes
In the past 12 months, Gilead Sciences has paid 211.00M in taxes.
Income Tax211.00M
Effective Tax Rate0.31
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 29.75, with an EV/FCF ratio of 12.80.
EV to Sales4.59
EV to EBITDA29.75
EV to Free Cash Flow12.80
EV to Operating Cash Flow12.18
Balance Sheet
Gilead Sciences has $7.93B in cash and marketable securities with $0.00 in debt, giving a net cash position of -$7.93B billion.
Cash & Marketable Securities$7.93B
Total Debt$0.00
Net Cash-$7.93B
Net Cash Per Share-$6.36
Tangible Book Value Per Share-$7.23
Margins
Gross margin is 80.30%, with operating margin of 5.78%, and net profit margin of 1.67%.
Gross Margin80.30%
Operating Margin5.78%
Pretax Margin2.40%
Net Profit Margin1.67%
EBITDA Margin15.42%
EBIT Margin5.80%
Analyst Forecast
The average price target for Gilead Sciences is $116.29, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$116.29
Price Target Upside20.00% Upside
Analyst ConsensusModerate Buy
Analyst Count26
Revenue Growth Forecast4.63%
EPS Growth Forecast1144.01%